Kartik Venkatachalam, PhD, is a Professor at The University of Texas Health Science Center at Houston. His research program takes a multi-tiered approach to understanding nervous system function, focusing on signal transduction mechanisms, synaptic development, vesicular trafficking, and decision-making processes in neural circuits. Research Interests: Identification of novel components regulating synaptic growth and connectivity ('synaptic developtome') Molecular mechanisms of endosomal/lysosomal trafficking relevant to neurodegeneration and cancer Neuronal network dynamics underlying decision-making in adult Drosophila TRP channel function in endolysosomal pathways and cellular homeostasis His publications demonstrate consistent focus on ion channel biology (particularly TRP channels), vesicular trafficking mechanisms, synaptic regulation, and Drosophila neurobiology. Recent work emphasizes the connection between lysosomal function, nutrient sensing (mTORC1 pathway), and neurodevelopmental processes.
Prof. Dr. Ute Höcker is a Professor at the Institute for Plant Sciences, University of Cologne. Her research focuses on plant molecular biology, particularly in the areas of light signaling, protein degradation, and chloroplast biogenesis. She leads a research group that investigates the molecular mechanisms underlying plant development and adaptation. Her research interests include: Light-controlled development in Arabidopsis thaliana Role of photoreceptors and the COP1/SPA ubiquitin ligase in seedling deetiolation, anthocyanin accumulation, and flowering time regulation Evolutionary studies in charophyte algae and mosses Transcription factors in chloroplast differentiation Plant adaptation to environmental conditions Her recent publications (2019-2023) predominantly explore light signaling pathways, protein degradation mechanisms, and chloroplast biogenesis across model plants including Arabidopsis and Physcomitrium patens. Key themes include the function of COP1/SPA complexes, cryptochrome interactions, and the regulation of photomorphogenesis. Prof. Höcker is an active member of the CEPLAS (Cluster of Excellence on Plant Sciences) initiative, which focuses on plant performance for sustainability. Her lab is part of the Plant Metabolism and Metabolomics Facility and utilizes the Imaging Platform and CEPLAS Data resources. She has been involved in funded research, including the CEPLAS cluster (funding period 2013-2018 and ongoing).
Dr. Marwan Suheimat is a Research Fellow at Queensland University of Technology's Faculty of Health, School of Clinical Sciences, specializing in advanced vision science research. His work focuses on ocular biometry, refractive error mechanisms, and myopia control interventions, collaborating extensively with leading researchers including Professor David Atchison. His primary research interests include Myopia Control , Accommodation Mechanisms , Peripheral Refraction Analysis , and Ocular Biomechanics . His investigations into choroidal thickness dynamics during accommodation and ciliary muscle dimension changes have provided critical insights into refractive error development. His methodological innovations in autorefractor technology and peripheral vision measurement have advanced clinical assessment protocols. Analysis of his recent publications reveals a strong emphasis on quantitative measurement techniques for studying ocular structures, with particular focus on myopia progression mechanisms and optical correction efficacy . His work bridges fundamental optical principles with clinical applications, particularly in developing improved diagnostic tools for vision science. Dr. Suheimat's research program demonstrates consistent productivity with high-impact publications in premier vision science journals including Ophthalmic and Physiological Optics , Investigative Ophthalmology & Visual Science , and Biomedical Optics Express , reflecting his significant contributions to understanding the optical and biomechanical properties of the human eye.
Jing Chen, PhD, is a Professor in the Department of Ophthalmology at Harvard Medical School and leads the Chen Laboratory at Boston Children's Hospital. Her research focuses on retinal vascular biology in development and pathological vascular eye diseases. The Chen Laboratory investigates retinal vascular biology with emphasis on pathological vascular eye diseases including retinopathy of prematurity, age-related macular degeneration, and rare hereditary diseases such as familial exudative vitreoretinopathy (FEVR) and Norrie disease. Her research program is structured around three main projects: nuclear receptor-mediated ocular neovascularization and inflammation; small non-coding RNAs in retinal angiogenesis; and Wnt signaling control of vascular growth and permeability in retinopathy. Analysis of Dr. Chen's recent publications reveals consistent focus on molecular mechanisms underlying retinal vascular diseases, with particular emphasis on nuclear receptor signaling (especially RORalpha), Wnt pathway regulation, and microRNA function in ocular angiogenesis. Her work spans basic molecular mechanisms to potential therapeutic applications, with numerous studies utilizing animal models to investigate disease pathogenesis. As principal investigator of the Chen Laboratory, Dr. Chen oversees research investigating disease mechanisms and potential therapeutics for vascular eye diseases. Her laboratory work involves multiple approaches including molecular biology, animal modeling, and translational research aimed at understanding and treating retinal vascular pathologies.
Dr. Benjamin Sivyer is a leading researcher in visual neuroscience specializing in retinal circuitry and neuronal dysfunction, particularly in the context of glaucoma. He directs the Sivyer Lab and serves as principal investigator on multiple NIH-funded research projects focused on understanding how eye diseases disrupt normal retinal processing. His research interests center on visual neuroscience, neural circuits, electrophysiology, and glaucoma. Dr. Sivyer employs an integrative approach combining multielectrode array systems, patch-clamp recordings, high-resolution confocal microscopy, behavioral studies, and transcriptomic analyses to investigate visual processing mechanisms in both healthy and diseased retinas. His work particularly focuses on how axon injury and diseases like glaucoma disturb normal retinal function. Dr. Sivyer's publication record demonstrates consistent contributions to understanding retinal ganglion cells, direction selectivity mechanisms, and glaucoma-related neurodegeneration. His recent work (2023-2025) shows increasing focus on molecular and spatial analysis techniques, neuroprotection in glaucoma, and advanced imaging methods for studying retinal structure and function. His research bridges fundamental neuroscience with clinical applications in ophthalmology. His scientific achievements include the NHMRC CJ Martin Biomedical Research Fellowship awarded in 2015. His current research is supported by multiple NIH grants including: NIH NEI 1R01EY034973 (2023-28) NIH NEI 1R01EY032564 (2022-27) NIH NEI 2R01 EY027202 (2022-26) NIH NEI U24EY033269 (2021-26) NIH NEI R01 EY030429 (2020-25) Dr. Sivyer's lab employs advanced techniques for visualizing and recording from retinal neurons to understand disease mechanisms. His research group investigates how retinal circuits process visual information and how these circuits are perturbed by disease, with particular emphasis on glaucoma as a model of retinal ganglion cell degeneration.
Dr. Xinhua Shu is a Reader (equivalent to Associate Professor) in Biological and Biomedical Sciences at Glasgow Caledonian University. With an h-index of 33 and 4016 citations from 118 research outputs, Dr. Shu maintains an active and impactful research program spanning molecular biology, neuroscience, and translational medicine. Dr. Shu's research focuses on: Zebrafish models for disease research (100% focus) Retinal pigment Epithelium (81% focus) Age-related Macular Degeneration (78% focus) Retinitis pigmentosa (78% focus) Photoreceptor Cell biology (70% focus) TSPO ligands and their therapeutic applications Recent research trends show Dr. Shu expanding into Alzheimer's disease research through TSPO ligands while maintaining strong work in retinal biology and degeneration. The research employs diverse methodologies including zebrafish models, molecular biology techniques, and polyomics approaches to address fundamental questions in neurodegeneration and retinal diseases. Notable scientific contributions include: Development of therapy for age-related macular degeneration Evaluating protective effects of TSPO ligands in Alzheimer's disease mouse models Research on domoic acid toxicity in the retina Investigations into Xuebijing's molecular mechanisms against sepsis Dr. Shu has secured research funding from organizations including the Scottish Funding Council and maintains an active presence in the academic community through invited talks and collaborations. With 20 recorded academic activities and supervision of multiple students, Dr. Shu contributes significantly to both research and academic training in biomedical sciences.
Meike Burow serves as Professor in the Department of Plant and Environmental Sciences within the Faculty of Science at the University of Copenhagen (UCPH), Denmark. Her research group operates under the Section for Plant Glycobiology, focusing on metabolic and regulatory networks in plant systems. Her educational background includes a Dipl. Biol. with excellence from the University of Hannover (2001) and a Dr. rer. nat. summa cum laude from Friedrich Schiller Universität Jena (2008). Prior academic positions include Associate Professor at UCPH (2011-2020), Postdoc/Assistant Professor in Plant Biology and Biotechnology (2008-2011), and research positions in Germany. Professor Burow's research centers on plant metabolic networks, particularly investigating how plants integrate internal and external signals through transcriptional, post-transcriptional, and post-translational regulation. Her work primarily utilizes Arabidopsis thaliana and glucosinolates as model systems to study specialized metabolism dynamics. Key research areas include transcription factor networks (particularly R2R3 MYB factors), metabolite sensing, RNA-mediated regulation, and protein-protein interactions in metabolic channeling. Her recent publications (2023-2025) demonstrate strong focus on plant defense mechanisms, glucosinolate metabolism, plant-microbe interactions, and translational applications in horticulture. The research spans molecular genetics, ecological interactions, and agricultural applications, with particular emphasis on Brassicaceae species and their specialized metabolites. As an educator, she serves as Head of Studies for the BSc Biotechnology program and teaches courses including Introduction to Biotechnology, Experimental Molecular Biology, and Big Data in Biotechnology at both undergraduate and graduate levels. Her outreach activities include public engagement events like Kulturnat in 2008-2009 focused on plant biotechnology. Her laboratory investigates the complex regulatory networks controlling plant specialized metabolism, with particular attention to how environmental cues modulate metabolic investments in growth versus defense. Current work integrates molecular techniques with systems biology approaches to understand metabolic plasticity in changing environments.
Patrick Griffin is a Professor and Scientific Director at The Scripps Research Institute (TSRI) Scripps Florida, where he serves in the Department of Molecular Therapeutics. With over 25 years of experience in drug discovery and development, Dr. Griffin has established himself as a leading researcher in protein structure and nuclear receptor signaling. His career spans both industry and academia, with significant contributions to pharmaceutical development including key work on Januvia (a DPP4 inhibitor now in clinical use). Ph.D. in Chemistry from the University of Virginia under Professor Donald F. Hunt Postdoctoral Fellowship with Professor Leroy Hood at Caltech Former Chief Science Officer at ExSAR Corporation Former Senior Director of Chemistry at Merck Research Laboratories Dr. Griffin's research program focuses on understanding nuclear receptor (NR) signaling using structural, chemical and biological approaches. His laboratory has made significant contributions to understanding the mechanism of ligand activation of NRs such as PPARs, RORs, REV-ERBs, LRH1, VDR, ER, GR, and PR. Through the use of mutagenesis, HDX-MS, crystallography, proteomics and genomics, his team studies the structure-function relationships of nuclear receptors, enzymes, and G protein coupled receptors (GPCRs). A major emphasis of his chemical biology program is developing functionally selective and promoter-specific modulators targeting diseases such as cancer, autoimmune disorders, obesity, and diabetes. Dr. Griffin's lab is particularly well-known for developing and applying biophysical methods including HDX and XL-MS platforms for analyzing protein plasticity, with a focus on nuclear receptors, enzymes, and GPCRs. Dr. Griffin's recent publications (2022-2025) demonstrate continued innovation in structural proteomics, nuclear receptor biology, and therapeutic development. His work shows a clear trajectory from fundamental protein structure research toward translational applications, particularly in metabolic disorders, cancer, and neurological conditions. A significant theme across his recent work is the development of non-muscle myosin II inhibitors with therapeutic potential, reflecting his long-standing interest in protein structure-function relationships and their therapeutic modulation. His research continues to bridge structural biology, chemical biology, and drug discovery, with particular emphasis on nuclear receptor signaling pathways and their role in metabolic regulation. Dr. Griffin's research impact is evidenced by his publication record of over 240 peer-reviewed manuscripts, an h-index of 83 (58 since 2016), and an i10-index of 223 according to Google Scholar. Dr. Griffin has served as PI, Co-PI, and co-investigator on numerous NIH-funded grants. Notable funding includes leadership of "The Comprehensive Center for Chemical Probe Discovery and Optimization at Scripps," a 6-year U54 MLPCN Roadmap initiative. He co-founded Ember, a biotech company funded by Third Rock Ventures, based on work from a RC4 collaboration with Bruce Spiegelman at Dana Faber. Dr. Griffin has maintained a 13-year collaboration with Eli Lilly and serves as PI on grants with private biotechs including Synkine Therapeutics. As Co-PI on a NIH Blueprint UH3 grant, he co-founded Myosin Therapeutics, whose clinical candidate emerged from this NIH-funded program. Dr. Griffin leads a research program that integrates structural biology, chemical biology, and drug discovery approaches. His laboratory has developed advanced HDX-MS and XL-MS platforms for protein structure analysis. The team's work spans from fundamental protein structure studies to translational drug discovery, with particular expertise in nuclear receptor biology. His lab has made significant contributions to understanding nuclear receptor signaling mechanisms and developing novel therapeutic approaches targeting these pathways.
Patrick Griffin is Professor and former Chair of the Department of Molecular Therapeutics at The Scripps Research Institute, with over 25 years of experience in protein structure research and drug discovery. His career spans both industry and academia, with significant contributions to structural proteomics and nuclear receptor pharmacology. Dr. Griffin earned his Ph.D. in Chemistry from the University of Virginia under Professor Donald F. Hunt, where he contributed to groundbreaking work in protein sequencing using tandem mass spectrometry. He completed postdoctoral training with Professor Leroy Hood at Caltech before holding leadership positions at Merck Research Laboratories and ExSAR Corporation. His research program focuses on protein structure-function relationships, particularly mutational- and ligand-mediated alterations in protein structural plasticity. Using mutagenesis, HDX-MS, crystallography, proteomics and genomics, his laboratory investigates nuclear receptors (PPARs, RORs, REV-ERBs, LRH1, VDR), enzymes, and GPCRs. The lab has made significant contributions to understanding ligand activation mechanisms and developing functionally selective modulators for diseases including cancer, autoimmune disorders, obesity, and diabetes. Analysis of Dr. Griffin's recent publications reveals a strong emphasis on nuclear receptor structural biology, particularly PPAR family members, with increasing integration of structural proteomics techniques to study therapeutic targets. His work shows a clear trajectory from basic structural understanding to therapeutic applications, with multiple discoveries translated into clinical candidates. Dr. Griffin serves as PI or Co-PI on multiple NIH-funded projects including a U54 MLPCN Roadmap initiative, RC4 programs, and U19 NCDDDG grants. He maintains a 13-year collaboration with Eli Lilly and has co-founded biotech companies including Ember and Myosin Therapeutics based on his research findings. His laboratory has developed advanced biophysical methods, particularly in HDX and XL-MS platforms for analyzing protein plasticity. The research group operates at the intersection of structural biology, chemical biology, and translational medicine, with strong industry partnerships facilitating the translation of basic discoveries into therapeutic candidates.
Kirill Martemyanov is a distinguished Professor at the University of Minnesota leading the Martemyanov Laboratory, with extensive research focused on G protein coupled receptor (GPCR) signaling pathways and their critical roles in neuronal systems. His work spans neuroscience, pharmacology, and vision research, with particular emphasis on understanding GPCR signaling in basal ganglia and retinal function. Dr. Martemyanov's research interests center on the fundamental principles regulating GPCR signaling, with specific focus on basal ganglia where G proteins mediate reward behavior and movement coordination, and in the retina where G protein signaling systems enable visual processing. His laboratory investigates Regulator of G protein Signaling (RGS) proteins, which promote G protein inactivation and serve as central control points in GPCR signaling cascades. His multidisciplinary approach combines proteomics, enzyme kinetics, cell culture studies, and behavioral characterization of genetic mouse models. Analysis of his recent publications reveals a strong focus on neurodevelopmental disorders, opioid signaling mechanisms, visual processing, and structural characterization of GPCRs. His work demonstrates consistent innovation in understanding G protein pathways, with increasing emphasis on therapeutic applications for movement disorders, vision pathologies, and addiction. John J. Abel Award 2018 ASPET Cogan Award 2014 McKnight Land-Grant Professorship 2008 European Academy Prize in Biology 1998 Dr. Martemyanov serves as Principal Investigator on multiple NIH-funded grants focusing on GPCR signaling in neuronal systems, opioid receptor mechanisms, and retinal biology. His laboratory employs cutting-edge techniques including cryo-EM, in vivo protein labeling, and genetic mouse models to investigate fundamental signaling mechanisms with therapeutic implications. Current research directions include discovery of novel G protein regulators, protein-protein interactions, and feedback mechanisms in signaling pathways. The Martemyanov Laboratory operates at the intersection of neuroscience and pharmacology, investigating how GPCR signaling pathways influence critical biological processes from cellular reception to synaptic transmission. The lab's research has significant implications for understanding and treating neurological disorders including Parkinson's disease, Huntington's disease, Tourette syndrome, tardive dyskinesia, and various ocular pathologies.
Andrew F.X. Goldberg serves as the Reddy Professor of Biomedical Sciences at the Eye Research Institute within Oakland University's William Beaumont School of Medicine. His research targets retinal degenerative diseases affecting over 2 million Americans, focusing on photoreceptor structure and function to develop therapies for inherited vision loss. Education: B.S. in Biochemistry/Philosophy from Binghamton University (1985) Ph.D. in Biochemistry from Brandeis University (1992) Postdoctoral training in Photoreceptor structure at University of British Columbia (1997) Postdoctoral training in Photoreceptor function at University of Washington (1998) Dr. Goldberg's laboratory employs biochemical, biophysical, and molecular genetic techniques across in vitro, in cellulo, and in vivo models to dissect how genetic defects compromise rod and cone photoreceptor architecture. His work bridges fundamental neuroscience with clinical ophthalmology, emphasizing translational pathways from molecular mechanisms to therapeutic interventions for conditions like retinitis pigmentosa. The research program maintains strong interdisciplinary connections between biochemistry, neural tissue specialization, and vision science. He secures funding from major organizations including the National Science Foundation, National Eye Institute, Foundation Fighting Blindness, The Grass Foundation, E. Matilda Zeigler Foundation, Research Excellence Fund (Oakland University), and Mid-West Eyebanks. Professional affiliations: Association for Research in Vision and Ophthalmology (ARVO) American Society for Biochemistry and Molecular Biology (ASBMB) Society for Neuroscience (SfN) Biophysical Society Dr. Goldberg leads the Goldberg Laboratory with a mission to elucidate the molecular basis of photoreceptor cellular structure, establishing rational foundations for designing novel therapies against blinding retinal degenerations. The lab emphasizes the critical relationship between retinal photoreceptor biology and human vision preservation.
